India, Aug. 27 -- Gilead Sciences, Inc. (GILD) on Thursday announced that the U.S. FDA has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen for the treatment of HIV in virologically suppressed adults.
Bixlenvo is the first single-tablet regimen (STR) indicated for virologically suppressed adults who are unable to take currently available STRs, including those on complex HIV treatment regimens.
Bixlenvo combines bictegravir, an integrase strand transfer inhibitor, with Sunlenca (lenacapavir), a capsid inhibitor with a novel mechanism of action and no cross-resistance to other antiretrovirals.
The regimen requires a two-day initiation dose with lenacapavir, followed by once-daily oral Bixlenvo.
T...